Skip to search formSkip to main contentSkip to account menu

Pivanex

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pivalyloxymethyl butyrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)
Histone deacetylase inhibitory prodrugs that are metabolized to butyric acid and formaldehyde possess antineoplastic properties… 
2007
2007
Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
Highly Cited
2004
Highly Cited
2004
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
2004
2004
Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer.
7279 Background: Pivanex is a histone deacetylase inhibitor that induces tumor cell differentiation and/or apoptosis. It has been… 
2004
2004
Pivanex inhibits histone deacetylase activity in non small cell lung cancer patients
4016 Pivanex™ (pivaloyloxymethyl butyrate) is a histone deacetylase (HDAC) inhibitor that distributes rapidly into tissues and… 
2004
2004
Changes to phase IIb Pivanex trial due to safety concerns
  • 2004
  • Corpus ID: 195151591
2004
2004
Changes to phase IIb Pivanex trial due to safety concerns
  • 2004
  • Corpus ID: 195112292
2003
2003
P-358 Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non-small cell lung cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)